Alkeus Pharmaceuticals, Inc. Sustainability Profile
Alkeus Pharmaceuticals, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for rare and serious diseases. Founded in 2011, Alkeus has made significant strides in the field of ophthalmology, particularly in addressing unmet medical needs associated with inherited retinal diseases. The company’s flagship product, a novel treatment for Stargardt disease, exemplifies its commitment to advancing patient care through unique therapeutic approaches. Alkeus is recognised for its robust pipeline and dedication to research, positioning itself as a leader in the rare disease sector. With a strong emphasis on scientific excellence and patient-centric solutions, Alkeus Pharmaceuticals continues to make impactful contributions to the biopharmaceutical landscape.
DitchCarbon Score
How does Alkeus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkeus Pharmaceuticals, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkeus Pharmaceuticals, Inc.'s reported carbon emissions
Alkeus Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Alkeus Pharmaceuticals may still be in the early stages of developing its climate commitments or reporting frameworks. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Alkeus to establish clear emissions reduction strategies and set ambitious targets in line with global climate goals. Without specific emissions data or commitments, it remains unclear how Alkeus Pharmaceuticals plans to address its environmental impact in the future.
How Carbon Intensive is Alkeus Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Alkeus Pharmaceuticals, Inc.'s Location?
Alkeus Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Alkeus Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
